Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
Br J Dermatol
; 153(1): 203-5, 2005 Jul.
Article
en En
| MEDLINE
| ID: mdl-16029352
ABSTRACT
Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Leishmania braziliensis
/
Anfotericina B
/
Leishmaniasis Cutánea
/
Antiprotozoarios
Límite:
Adult
/
Animals
/
Humans
/
Male
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Br J Dermatol
Año:
2005
Tipo del documento:
Article
País de afiliación:
Reino Unido